

Ajanta House Charkop, Kandivli West, Mumbai 400 067 India T +91 22 6606 1000 F +91 22 6606 1200 E info@ajantapharma.com W www.ajantapharma.com

14th November 2022

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai - 400 001 National Stock Exchange of India Exchange Plaza, 5th Floor, Plot No. C/1, G block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051

Scrip Code: BSE - AJANTPHARM 532331

Scrip Code: NSE AJANTPHARM EQ

Subject: - Disclosure of Related Party Transactions pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements), 2015

Dear Sir / Madam,

Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed disclosure of Related Party Transactions in the prescribed format for the half year ended 30th September 2022.

Kindly take the same on your records.

Thanking you,

Yours faithfully,

Gaurang Shah

VP – Legal & Company Secretary

Encl.: a/a

Disclosure of Related Party Transaction for the half year ended 30th September 2022

Rs. (in crs)

| | oarty transact | | | | | | | | | | | | | Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-co deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during period when such transaction was undertaken. | | | | | | | | |
|----------------|-------------------------------------------------------------------|-----------------|--------------------------------------------------|-----|---------------------------------------------------------------------------------|-----------------------------------|------------------------------------------------|-----------------------------------------------------------------|--------------------------------------------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------------------|--------------------|------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|----------------------------------------------------------------------------|-------------------------------|-----------------------|--------------------------------------------------------------------------------------------------------------|-------|--|--|
| | eails of the par entity /subsic entering into transactio | diary) o the | Details of the counterparty | | | Type of related party transaction | Details of other related party transaction | Value of the related party transaction as approved by the audit | Remarks on approval by audit committee | Value of transaction during the reporting period | In case monies are due to either party as a result of the transaction | | make or g | financial indebtedness i vive loans, inter-corporal advances or investment | e deposits, | Details of th | ne loans, inter-corporate dep | osits, advance | s or investments | Notes | | |
| | Name | PAN | Name | PAN | Relationship of the counterparty with the listed entity or its subsidiary | | | committee | | | Opening balance | Closing balance | Nature of indebtednes s (loan/ issuance of debt/ any other etc.) | Details of other indebtednes s | Tenure | Nature (loan/ advance/ intercorpora te deposit/ investment) | Interest Rate (%) | Secured/ unsecured | Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage) | | | |
| 1 Ajar Lim | nta Pharma ted | | Ajanta Foundation | | Company is able to exercise significant control over this entity | Any other transaction | Corporate Social Responsibility expense | 1.00 | Transactions are carried out on arms length basis and in ordinary course of business | 0.05 | 0.00 | 0.00 | | | | | | | | | | |
| 2 Ajar Lim | nta Pharma ted | | M/s. Al Packaging | | Relative of Chairman | Purchase of goods or services | | 10.00 | Transactions are carried out on arms length basis and in ordinary course of business | 4.65 | 0.00 | 0.00 | | | | | | | | 1 | | |
| 3 Ajar Lim | nta Pharma ted | | M/s. AI Packaging | | Relative of Chairman | Any other transaction | Trade Payable | | N.A. | 0.00 | 0.95 | 0.68 | 3 | | | | | | | | | |
| 4 Ajar Lim | nta Pharma ted | | Ajanta Pharma (Mauritius) Ltd | | Subsidiary | Sale of goods or services | | 75.00 | Transactions are carried out on arms length basis and in ordinary course of business | 25.94 | 0.00 | 0.00 | | | | | | | | | | |
| 5 Ajar Lim | nta Pharma ted | | Ajanta Pharma (Mauritius) Ltd | | Subsidiary | Any other transaction | Trade Receivables | | N.A. | 0.00 | 42.30 | 28.25 | | | | | | | | | | |
| 6 Ajar | nta Pharma ted | | Ajanta Pharma (Mauritius) Ltd | | Subsidiary | Any other transaction | Trade Payable | | N.A. | 0.00 | 0.17 | 0.00 | | | | | | | | | | |
| 7 Ajar Lim | nta Pharma ted | | Ajanta Pharma Limited Group Gratuity Trust | | Company is able to exercise significant control over this entity | Any other transaction | Contribution to employment benefit plans | | N.A. | 6.47 | 0.00 | 0.00 |) | | | | | | | | | |
| 8 Ajar Lim | nta Pharma ted | | Ajanta Pharma Nigeria Ltd | | Subsidiary | Any other transaction | Reimbursement of expenses | | N.A. | 0.10 | 0.00 | 0.00 | | | | | | | | | | |
| 9 Ajar Lim | nta Pharma ted | | Ajanta Pharma Nigeria Ltd | | Subsidiary | Any other transaction | Advance Given | | N.A. | 0.00 | 0.07 | 0.06 | j | | | | | | | | | |
| 10 Ajar Lim | nta Pharma ted | | Ajanta Pharma Philippines Inc. | | Subsidiary | Sale of goods or services | | 170.00 | Transactions are carried out on arms length basis and in ordinary course of business | 64.84 | 0.00 | 0.00 | | | | | | | | | | |
| 11 Ajar Lim | nta Pharma ted | | Ajanta Pharma Philippines Inc. | | Subsidiary | Any other transaction | Trade Receivables | | N.A. | 0.00 | 41.75 | 39.66 | | | | | | | | | | |
| 12 Ajar | nta Pharma ted | | Ajanta Pharma Philippines Inc. | | Subsidiary | Investment | | | N.A. | 0.00 | 1.38 | 1.38 | 3 | | | | | | | | | |

Rs. (in crs)

| relate | ed party transac | tions | | | | | | | | | | | | | y transactions - applicable nade or given by the listed reporting period when | entity/subsidia | ry. These deta | ils need to be | | |
|-------------|-----------------------------------------------------------------------------------------|-------|---------------------------|-------------------------------------------------------------------------------|-----------------------------------|--------------------------------------------------|-----------------------------------------------------------------------------|--------------------------------------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------------------------|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------|------|-------------------------------------------------------------------------------------|-----------------|----------------|-----------------------|--------------------------------------------------------------------------------------------------------------|-------|
| No I | Details of the party (listed entity /subsidiary) entering into the transaction | | Deta | ails of the counterparty | Type of related party transaction | Details of other related party transaction | Value of the related party transaction as approved by the audit | Remarks on approval by audit committee | Value of transaction during the reporting period | In case monies are due to either party as a result of the transaction | | In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments advances or investments | | | | | | | | Notes |
| | Name | PAN | Name | PAN Relationship of the counterparty with the listed entity or its subsidiary | | | committee | | | Opening balance | Closing balance | indebtednes | etails of other lebtednes s | Cost | Tenure (loan/ advance/ intercorpora te deposit/ investment | | e Tenure | Secured/ unsecured | Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage) | ı |
| | Ajanta Pharma Limted | | Ajanta Pharma USA Inc. | Subsidiary | Sale of goods or services | | 600.00 | Transactions are carried out on arms length basis and in ordinary course of business | 241.88 | 0.00 | 0.00 | | | | | | | | | |
| | Ajanta Pharma Limted | | Ajanta Pharma USA Inc. | Subsidiary | Any other transaction | Other Income | 1.50 | Transactions are carried out on arms length basis and in ordinary course of business | 0.57 | 0.00 | 0.00 | | | | | | | | | |
| 15 A | Ajanta Pharma Limted | | Ajanta Pharma USA Inc. | Subsidiary | Any other transaction | Trade Receivables | | N.A. | 0.00 | 661.68 | 642.27 | 7 | | | | | | | | |
| 16 A | Ajanta Pharma Limted | | Ajanta Pharma USA Inc. | Subsidiary | Any other transaction | Other Receivables | | N.A. | 0.00 | 0.44 | 1.05 | 5 | | | | | | | | |
| 17 A | Ajanta Pharma Limted | | Ajanta Pharma USA Inc. | Subsidiary | Investment | | | N.A. | 0.00 | 7.07 | 7.07 | 7 | | | | | | | | |
| 18 A | Ajanta Pharma Limted | | Arvind Agrawal | Chief Financial Officer & KMP | Any other transaction | Short Term Employee benefits | | N.A. | 0.82 | 0.00 | 0.00 |) | | | | | | | | |
| | Ajanta Pharma Limted | | Arvind Agrawal | Chief Financial Officer & KMP | Any other transaction | Post Employment Benefits | | N.A. | 0.01 | 0.00 | 0.00 |) | | | | | | | | |
| 20 <i>A</i> | Ajanta Pharma Limted | | Chandrakant M. Khetan | Independent Director | Any other transaction | Sitting fees paid | | N.A. | 0.03 | 0.00 | 0.00 |) | | | | | | | | |
| 21 A | Ajanta Pharma Limted | | Chandrakant M. Khetan | Independent Director | Any other transaction | Commission to Directors | | N.A. | 0.02 | 0.00 | 0.00 |) | | | | | | | | |
| | Ajanta Pharma Limted | | Chandrakant M. Khetan | Independent Director | Any other transaction | Commission payable | | N.A. | 0.00 | 0.04 | 0.02 | 2 | | | | | | | | |
| 23 / | Ajanta Pharma | | Dr. Anjana Grewal | Independent Director | Any other | Sitting fees paid | | N.A. | 0.01 | 0.00 | 0.00 | | | | | | | | | |
| 24 A | <u>Limted</u> Ajanta Pharma Limted | | Dr. Anjana Grewal | Independent Director | transaction Any other transaction | Commission to Directors | | N.A. | 0.01 | 0.00 | 0.00 | | | | | | | | | |
| 25 <i>E</i> | Ajanta Pharma Limted | | Dr. Anjana Grewal | Independent Director | Any other transaction | Commission payable | | N.A. | 0.00 | 0.02 | 0.01 | ı | | | | | | | | |
| | Ajanta Pharma Limted | | Gaurang Shah | Company Secretary & KMP | Any other transaction | Short Term Employee benefits | | N.A. | 0.46 | 0.00 | 0.00 | | | | | | | | | |
| 27 A | Ajanta Pharma Limted | | Gaurang Shah | Company Secretary & KMP | Any other transaction | Post Employment Benefits | | N.A. | 0.02 | 0.00 | 0.00 | | | | | | | | | |

Rs. (in crs)

| | ted party transactions | | | | | | | | | | | | Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-cor deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, dur reporting period when such transaction was undertaken. | | | | | | | | | |
|-------------|-----------------------------------------------------------------------------------------|-----|-----------------------------------------------------------|-----|------------------------------------------------------------------------------|-----------------------------------|--------------------------------------------------|-----------------------------------------------------------------|--------------------------------------------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------------------------|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|------|--------------------------------------------------------------|-------------------------------|---------------|--------|-----------------------|--------------------------------------------------------------------------------------------------------------|-------|
| r No | Details of the party (listed entity /subsidiary) entering into the transaction | | | | | Type of related party transaction | Details of other related party transaction | Value of the related party transaction as approved by the audit | committee | Value of transaction during the reporting period | In case monies are due to either party as a result of the transaction | | In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments advances or investments | | | | | | | | | Notes |
| | Name | PAN | Name | PAN | Relationship of the counterparty with the listed entity or its subsidiary | | | committee | | | Opening balance | Closing balance | Nature of indebtednes s (loan/ issuance of debt/ any other etc.) | Details of other indebtednes s | Cost | Tenure Nati (loa advai interco te dep investr | n/ (f ce/ pora osit/ | st Rate 6) | Tenure | Secured/ unsecured | Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage) | |
| 28 | Ajanta Pharma Limted | | K. H. Viswanathan | lı | ndependent Director | Any other transaction | Sitting fees paid | | N.A. | 0.03 | 0.00 | 0.00 |) | | | | | | | | | |
| 29 <i>i</i> | Ajanta Pharma Limted | | K. H. Viswanathan | lı | ndependent Director | Any other transaction | Commission to Directors | | N.A. | 0.01 | 0.00 | 0.00 |) | | | | | | | | | |
| 30 / | Ajanta Pharma Limted | | K. H. Viswanathan | lı | ndependent Director | Any other transaction | Commission payable | 2 | N.A. | 0.00 | 0.02 | 0.03 | 1 | | | | | | | | | |
| 31 | Ajanta Pharma Limted | | Madhusudan B. Agrawal | E | Executive Vice-Chairman | Any other transaction | Short Term Employee benefits | | N.A. | 1.91 | 0.00 | 0.00 |) | | | | | | | | | |
| 32 / | Ajanta Pharma .imted | | Madhusudan B. Agrawal | E | xecutive Vice-Chairman | Any other transaction | Post Employment Benefits | | N.A. | 0.05 | 0.00 | 0.00 |) | | | | | | | | | |
| 33 / | Ajanta Pharma .imted | | Mamta and Madhusudan Agrawal Memorial Foundation | e | Promoter group is able to exercise significant control over his entity | Any other transaction | Corporate Social Responsibility expense | 5.35 | Transactions are carried out on arms length basis and in ordinary course of business | 1.20 | 0.00 | 0.00 |) | | | | | | | | | |
| 34 | Ajanta Pharma | | Mannalal B. | | Non Executive Director - | Any other | Sitting fees paid | | N.A. | 0.03 | 0.00 | 0.00 |) | | | | | | | | | |
| 35 | <u>imted</u> Ajanta Pharma Limted | | Agrawal Prabhakar Dalal | | Chairman ndependent Director | transaction Any other transaction | Sitting fees paid | | N.A. | 0.02 | 0.00 | 0.00 |) | | | | | | | | | |
| ı | Ajanta Pharma Limted | | Prabhakar Dalal | lı | ndependent Director | Any other transaction | Commission to Directors | | N.A. | 0.01 | 0.00 | 0.00 |) | | | | | | | | | |
| 37 <i>i</i> | Ajanta Pharma Limted | | Prabhakar Dalal | lı | ndependent Director | Any other transaction | Commission payable | 2 | N.A. | 0.00 | 0.02 | 0.01 | L | | | | | | | | | Ì |
| 38 / | Ajanta Pharma .imted | | Rajesh M. Agrawal | J | oint Managing Director & KMP | Any other transaction | Short Term Employee benefits | | N.A. | 6.17 | 0.00 | 0.00 |) | | | | | | | | | |
| 39 / | Ajanta Pharma Limted | | Rajesh M. Agrawal | J | oint Managing Director & KMP | | Post Employment Benefits | | N.A. | 0.13 | 0.00 | 0.00 | | | | | | | | | | |
| 40 | Ajanta Pharma Limted | | Rajesh M. Agrawal | J | oint Managing Director & KMP | Any other transaction | Commission to Directors | | N.A. | 2.63 | 0.00 | 0.00 | | | | | | | | | | |
| 41 / | Ajanta Pharma .imted | | Rajesh M. Agrawal | J | oint Managing Director & KMP | Any other transaction | Commission payable | | N.A. | 0.00 | 5.25 | 2.63 | 3 | | | | | | | | | |
| | Ajanta Pharma .imted | | Seth Bhagwandas Agarwal Charitable Trust | e | Promoter group is able to exercise significant control over his entity | Any other transaction | Corporate Social Responsibility expense | 1.00 | Transactions are carried out on arms length basis and in ordinary course of business | 0.90 | 0.00 | 0.00 | | | | | | | | | | |

Rs. (in crs)

| elated party transa | | | | | | | | | | | | | | ents made or g | iven by the listed | e only in case the related par d entity/subsidiary. These de n such transaction was under | ails need to be | | | |
|-----------------------------------------------------------------|-------------------|-----------------------------------------------------|-----|---------------------------------------------------------------------------|-----------------------------------|-----------------------------------------------|-----------------------------------------------------------------|--------------------------------------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------------------------|--------------------|---------------------------------------------------------------------------------|----------------------------------------------------------------|-----------------|-----------------------------------------------------------|-------------------------------------------------------------------------------------------------|-----------------------|--------------------------------------------------------------------------------------------------------------|--|--|
| No Details of the pa entity /subs entering in transact | idiary) to the | Details of the counterparty | | | Type of related party transaction | Details of other related party transaction | Value of the related party transaction as approved by the audit | committee | Value of transaction during the reporting period | In case monies are due to either party as a result of the transaction | | make or g | financial indebted ive loans, inter-co advances or inves | rporate deposit | | Details of the loans, inter-corporate deposits, advances or investments | | | | |
| Name | PAN | Name | PAN | Relationship of the counterparty with the listed entity or its subsidiary | | | committee | | | Opening balance | Closing balance | Nature of indebtednes s (loan/ issuance of debt/ any other etc.) | Details of other indebtednes s | Cost Tenui | re Nature (loan/ advance/ intercorpo te deposit investmen | ra t/ | Secured/ unsecured | Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage) | | |
| 43 Ajanta Pharma Limted | | Tanya Agrawal | | Daughter of Managing Director | Any other transaction | Short Term Employee benefits | | Transactions are carried out on arms length basis and in ordinary course of business | 0.05 | 0.00 | 0.00 | | | | | | | | | |
| 44 Ajanta Pharma Limted | | Tanya Agrawal | | Daughter of Managing Director | Any other transaction | Post Employment Benefits | | N.A. | 0.00 | 0.00 | 0.00 | | | | | | | | | |
| 45 Ajanta Pharma Limted | | Yogesh M. Agrawal | | Managing Director & KMP | Any other transaction | Short Term Employee benefits | | N.A. | 6.17 | 0.00 | 0.00 | | | | | | | | | |
| 46 Ajanta Pharma Limted | | Yogesh M. Agrawal | | Managing Director & KMP | Any other transaction | Post Employment Benefits | | N.A. | 0.14 | 0.00 | 0.00 | | | | | | | | | |
| 47 Ajanta Pharma Limted | | Yogesh M. Agrawal | | Managing Director & KMP | Any other transaction | Commission to Directors | | N.A. | 2.63 | 0.00 | 0.00 | | | | | | | | | |
| 48 Ajanta Pharma Limted | | Yogesh M. Agrawal | | Managing Director & KMP | Any other transaction | Commission payable | | N.A. | 0.00 | 5.25 | 2.63 | | | | | | | | | |
| 49 Ajanta Pharma Limted | | Ajanta Pharma (Mauritius) Ltd | | Subsidiary | Investment | | | N.A. | 0.00 | 9.44 | 9.44 | | | | | | | | | |
| 50 Ajanta Pharma Limted | | Ajanta Pharma Philippines Inc. | | Subsidiary | Dividend received | | | N.A. | 35.14 | 0.00 | 0.00 | | | | | | | | | |
| 51 Ajanta Pharma Limted | | Samta Puroshattam Agrawal Memorial Foundation | | Promoter group is able to exercise significant control over this entity | Any other transaction | Corporate Social Responsibility expense | 5.75 | Transactions are carried out on arms length basis and in ordinary course of business | 2.92 | 0.00 | 0.00 | | | | | | | | | |
| otal value of transac | tion during | the reporting period | | | 1 | | | | 406.02 | | l | <u> </u> | | | | | | | | |

Note: Amount approved by Audit Committee is for the entire financial year